Francesca Galardi1, Francesca De Luca1, Chiara Biagioni2, Ilenia Migliaccio1, Giuseppe Curigliano3,4, Alessandro M Minisini5, Martina Bonechi1, Erica Moretti6, Emanuela Risi6, Amelia McCartney6,7, Matteo Benelli2, Dario Romagnoli2, Silvia Cappadona6, Stefano Gabellini6, Cristina Guarducci1,8, Valerio Conti9, Laura Biganzoli6, Angelo Di Leo6, Luca Malorni10,11. 1. "Sandro Pitigliani" Translational Research Unit, Hospital of Prato, Prato, Italy. 2. Bioinformatics Unit, Hospital of Prato, Prato, Italy. 3. Division of Early Drug Development, Istituto Europeo di Oncologia, IRCCS, Milan, Italy. 4. Department of Haematology and Haemato-Oncology, University of Milan, Milan, Italy. 5. Department of Oncology, Azienda Sanitaria Universitaria del Friuli Centrale, Udine, Italy. 6. "Sandro Pitigliani" Medical Oncology Department, Hospital of Prato, Prato, Italy. 7. School of Clinical Sciences, Monash University, Melbourne, Australia. 8. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA. 9. Pediatric Neurology, Neurogenetics and Neurobiology Unit and Laboratories, Children's Hospital A. Meyer-University of Florence, Florence, Italy. 10. "Sandro Pitigliani" Translational Research Unit, Hospital of Prato, Prato, Italy. luca.malorni@uslcentro.toscana.it. 11. "Sandro Pitigliani" Medical Oncology Department, Hospital of Prato, Prato, Italy. luca.malorni@uslcentro.toscana.it.
Abstract
BACKGROUND: Circulating tumor cells (CTCs) are prognostic in patients with advanced breast cancer (ABC). However, no data exist about their use in patients treated with palbociclib. We analyzed the prognostic role of CTC counts in patients enrolled in the cTREnd study, a pre-planned translational sub-study of TREnd (NCT02549430), that randomized patients with ABC to palbociclib alone or palbociclib plus the endocrine therapy received in the prior line of treatment. Moreover, we evaluated RB1 gene expression on CTCs and explored its prognostic role within the cTREnd subpopulation. METHODS: Forty-six patients with ER-positive, HER2-negative ABC were analyzed. Blood samples were collected before starting palbociclib treatment (timepoint T0), after the first cycle of treatment (timepoint T1), and at disease progression (timepoint T2). CTCs were isolated and counted by CellSearch® System using the CellSearch™Epithelial Cell kit. Progression-free survival (PFS), clinical benefit (CB) during study treatment, and time to treatment failure (TTF) after study treatment were correlated with CTC counts. Samples with ≥ 5 CTCs were sorted by DEPArray system® (DA). RB1 and GAPDH gene expression levels were measured by ddPCR. RESULTS: All 46 patients were suitable for CTCs analysis. CTC count at T0 did not show significant prognostic value in terms of PFS and CB. Patients with at least one detectable CTC at T1 (n = 26) had a worse PFS than those with 0 CTCs (n = 16) (p = 0.02). At T1, patients with an increase of at least three CTCs showed reduced PFS compared to those with no increase (mPFS = 3 versus 9 months, (p = 0.004). Finally, patients with ≥ 5 CTCs at T2 (n = 6/23) who received chemotherapy as post-study treatment had a shorter TTF (p = 0.02). Gene expression data for RB1 were obtained from 19 patients. CTCs showed heterogeneous RB1 expression. Patients with detectable expression of RB1 at any timepoint showed better, but not statistically significant, outcomes than those with undetectable levels. CONCLUSIONS: CTC count seems to be a promising modality in monitoring palbociclib response. Moreover, CTC count at the time of progression could predict clinical outcome post-palbociclib. RB1 expression analysis on CTCs is feasible and may provide additional prognostic information. Results should be interpreted with caution given the small studied sample size.
BACKGROUND: Circulating tumor cells (CTCs) are prognostic in patients with advanced breast cancer (ABC). However, no data exist about their use in patients treated with palbociclib. We analyzed the prognostic role of CTC counts in patients enrolled in the cTREnd study, a pre-planned translational sub-study of TREnd (NCT02549430), that randomized patients with ABC to palbociclib alone or palbociclib plus the endocrine therapy received in the prior line of treatment. Moreover, we evaluated RB1 gene expression on CTCs and explored its prognostic role within the cTREnd subpopulation. METHODS: Forty-six patients with ER-positive, HER2-negative ABC were analyzed. Blood samples were collected before starting palbociclib treatment (timepoint T0), after the first cycle of treatment (timepoint T1), and at disease progression (timepoint T2). CTCs were isolated and counted by CellSearch® System using the CellSearch™Epithelial Cell kit. Progression-free survival (PFS), clinical benefit (CB) during study treatment, and time to treatment failure (TTF) after study treatment were correlated with CTC counts. Samples with ≥ 5 CTCs were sorted by DEPArray system® (DA). RB1 and GAPDH gene expression levels were measured by ddPCR. RESULTS: All 46 patients were suitable for CTCs analysis. CTC count at T0 did not show significant prognostic value in terms of PFS and CB. Patients with at least one detectable CTC at T1 (n = 26) had a worse PFS than those with 0 CTCs (n = 16) (p = 0.02). At T1, patients with an increase of at least three CTCs showed reduced PFS compared to those with no increase (mPFS = 3 versus 9 months, (p = 0.004). Finally, patients with ≥ 5 CTCs at T2 (n = 6/23) who received chemotherapy as post-study treatment had a shorter TTF (p = 0.02). Gene expression data for RB1 were obtained from 19 patients. CTCs showed heterogeneous RB1 expression. Patients with detectable expression of RB1 at any timepoint showed better, but not statistically significant, outcomes than those with undetectable levels. CONCLUSIONS: CTC count seems to be a promising modality in monitoring palbociclib response. Moreover, CTC count at the time of progression could predict clinical outcome post-palbociclib. RB1 expression analysis on CTCs is feasible and may provide additional prognostic information. Results should be interpreted with caution given the small studied sample size.
Authors: David T Miyamoto; Richard J Lee; Mark Kalinich; Joseph A LiCausi; Yu Zheng; Tianqi Chen; John D Milner; Erin Emmons; Uyen Ho; Katherine Broderick; Erin Silva; Sarah Javaid; Tanya Todorova Kwan; Xin Hong; Douglas M Dahl; Francis J McGovern; Jason A Efstathiou; Matthew R Smith; Lecia V Sequist; Ravi Kapur; Chin-Lee Wu; Shannon L Stott; David T Ting; Anita Giobbie-Hurder; Mehmet Toner; Shyamala Maheswaran; Daniel A Haber Journal: Cancer Discov Date: 2018-01-04 Impact factor: 39.397
Authors: J-Y Pierga; D Hajage; T Bachelot; S Delaloge; E Brain; M Campone; V Diéras; E Rolland; L Mignot; C Mathiot; F-C Bidard Journal: Ann Oncol Date: 2011-06-03 Impact factor: 32.976
Authors: R Condorelli; L Spring; J O'Shaughnessy; L Lacroix; C Bailleux; V Scott; J Dubois; R J Nagy; R B Lanman; A J Iafrate; F Andre; A Bardia Journal: Ann Oncol Date: 2018-03-01 Impact factor: 32.976
Authors: Massimo Cristofanilli; Daniel F Hayes; G Thomas Budd; Mathew J Ellis; Alison Stopeck; James M Reuben; Gerald V Doyle; Jeri Matera; W Jeffrey Allard; M Craig Miller; Herbert A Fritsche; Gabriel N Hortobagyi; Leon W M M Terstappen Journal: J Clin Oncol Date: 2005-03-01 Impact factor: 44.544
Authors: Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; Jeri Matera; M Craig Miller; James M Reuben; Gerald V Doyle; W Jeffrey Allard; Leon W M M Terstappen; Daniel F Hayes Journal: N Engl J Med Date: 2004-08-19 Impact factor: 91.245
Authors: Maria Teresa Herrera-Abreu; Marta Palafox; Uzma Asghar; Martín A Rivas; Rosalind J Cutts; Isaac Garcia-Murillas; Alex Pearson; Marta Guzman; Olga Rodriguez; Judit Grueso; Meritxell Bellet; Javier Cortés; Richard Elliott; Sunil Pancholi; José Baselga; Mitch Dowsett; Lesley-Ann Martin; Nicholas C Turner; Violeta Serra Journal: Cancer Res Date: 2016-03-28 Impact factor: 12.701
Authors: Cristina Guarducci; Martina Bonechi; Luca Malorni; Ilenia Migliaccio; Matteo Benelli; Chiara Biagioni; Giulia Boccalini; Dario Romagnoli; Roberto Verardo; Rachel Schiff; C Kent Osborne; Carmine De Angelis; Angelo Di Leo Journal: NPJ Breast Cancer Date: 2018-11-28